Translational Pathology Core Laboratory Shared Resource (TPCL)

转化病理学核心实验室共享资源 (TPCL)

• 批准号: 10619456
• 负责人: SAMUEL FRENCH
• 金额: $ 27.45万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-12-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10619456
• 关键词: Accreditation; Adopted; Adoptive Transfer; Algorithmic Analysis; American; Animals; Antibodies; Basic Science; Biopsy Specimen; Blood; Board Certification; CTAG1 gene; CTLA4 blockade; California; Cancer Center; Cancer Center Support Grant; Cell Separation; Cells; Clinical; Clinical Research; Clinical Trials; Collaborations; Color; Complex; Comprehensive Cancer Center; Computerized Medical Record; Consent; Consultations; Core Biopsy; County; Creativeness; Custom; Data; Development; Diagnostic; Disease; Doctor of Philosophy; Dryness; Electronics; Evaluation; Event; Fees; Formalin; Freezing; Fresh Tissue; Future; Glucose Transporter; Goals; Histology; Human; Image Analysis; Immunofluorescence Immunologic; Immunohistochemistry; Immunotherapy; In Situ Hybridization; Institutional Review Boards; International Classification of Disease Codes; Interventional radiology; Journals; Laboratories; Los Angeles; Lung Adenocarcinoma; Malignant Neoplasms; Medical Records; Microscopy; NCI Center for Cancer Research; Paraffin Embedding; Pathologist; Pathology; Patients; Peptides; Peripheral Blood Mononuclear Cell; Physiologic pulse; Population; Population Characteristics; Process; Publications; RNA; Research; Research Design; Research Personnel; Resistance; Resource Sharing; Retrieval; Route; Sampling; Services; Slide; Sodium; Specimen; Stains; System; T-Cell Receptor; Testing; Tissue Embedding; Tissue Procurements; Tissue Sample; Tissues; Translational Research; Universities; Visit; Work; anticancer research; biobank; clinical diagnostics; college; cost; dendritic cell vaccination; digital imaging; digital pathology; electronic consent; human tissue; improved; innovation; innovative technologies; ipilimumab; laser capture microdissection; medical schools; member; novel; programs; sample archive; therapeutic target; translational goal; tumor; tumor progression; virtual; ward

TRANSLATIONAL PATHOLOGY CORE LABORATORY SHARED RESOURCE (TPCL) ABSTRACT The Translational Pathology Core Laboratory (TPCL), a UCLA Jonsson Comprehensive Cancer Center (JCCC) Shared Resource since 1998, provides pathology services critical for basic, translational, clinical, and population cancer research. TPCL provides a College of American Pathologists accredited human tissue biobank, histology (animal/human; frozen/formalin-fixed paraffin embedded), laser capture microdissection, immunohistochemistry and in-situ hybridization services (established/new antibody optimization), and pathology consultation services. TPCL connects cancer researchers with subspecialty pathologists and was an early adopter of digital pathology, assisting with custom digital image analysis algorithms for complex evaluations of tissue sections. TPCL provided essential services and materials for numerous, recent high-impact studies, including work demonstrating that a sodium-glucose transporter is a potential diagnostic and therapeutic target in early-stage lung adenocarcinoma, and that therapy-induced tumor secretomes promote resistance and tumor progression. TPCL supports many clinical trials, including a recent UCLA-led investigator-initiated clinical trial of dual-cell immunotherapy, combining a NY-ESO-1 specific T cell receptor adoptively transferred with NY-ESO-1 peptide- pulsed dendritic cell vaccination, with or without ipilimumab-induced CTLA-4 blockade. During 2013 – 2018, TPCL developed four-color multiplexed immunofluorescence (MIF) staining for the Leica/Aperio slide scanner, which is a unique scanner capability, introduced nine-color MIF with a Perkin-Elmer Polaris system, created processes to identify and retrieve remnant biofluids with customized clinical variables, initiated a video universal electronic consent for biobanking, built research blood draw order capabilities within routine clinical lab orders, collaborated on a UC Virtual Biobank, and added biofluid acquisition, processing and storage. TPCL fees are similar to or lower than those of other cancer centers within Los Angeles County. During the prior project period, 153 JCCC members from all six Research Programs used TPCL representing 69% of overall usage. Their usage resulted in 334 publications, 49% of which were in high-impact (IF ≥10, or field leading) journals. TPCL is centrally located to most JCCC labs and occupies ~6,400 sf. TPCL Director Sarah Dry, MD (ZY), and Co-Directors Samuel French, MD, PhD (ZY) and Dawn Ward, MD, are board-certified, practicing pathologists who conduct basic, translational, and clinical research. Since 2013, Dry co-led the UCLA biobanking consent effort, with 39,700 consents in 24 months, using a novel video e-consent process. Dry also initiated efforts leading to current TPCL collaborations with UC Davis on a University of California (UC) Virtual Biobank. Exciting future TPCL directions to support and benefit JCCC research include: (1) Automated IF/combined IF/RNA-ISH staining; (2) Increased clinical variable searches for remnant biofluids; (3) Facilitated use of research blood draw requests by non-clinicians; and (4) Continued development of the UC Virtual Biobank.

转化病理学核心实验室共享资源（TPCL） 抽象的 UCLA Jonsson综合癌症中心（JCCC）的转化病理学核心实验室（TPCL） 自1998年以来共享资源提供对基本，翻译，临床和人群至关重要的病理服务 癌症研究。 TPCL提供了美国病理学家学院认可的人体组织生物库，组织学 （动物/人类；嵌入的冷冻/福尔马林固定石蜡），激光捕获显微解剖，免疫组织化学 和原位杂交服务（已建立/新抗体优化）和病理咨询服务。 TPCL将癌症研究人员与亚科病理学家联系起来，并且是数字病理学的早期采用者， 协助定制数字图像分析算法，以进行组织切片的复杂评估。 TPCL为许多最近的高影响研究提供了必不可少的服务和材料，包括工作 证明钠 - 葡萄糖转运蛋白是早期阶段的潜在诊断和治疗靶标 肺腺癌，该治疗诱导的肿瘤秘密症促进了抗药性和肿瘤进展。 TPCL支持许多临床试验，包括最近由UCLA领导的研究者发起的双细胞临床试验 免疫疗法，结合使用NY-ESO-ESO-1肽自适应转移的NY-ESO-1特异性T细胞受体 脉冲的树突状细胞疫苗接种，有或没有iPilimumab诱导的CTLA-4阻滞。 在2013年至2018年期间，TPCL开发了四色多重免疫荧光（MIF）的染色 Leica/Aperio幻灯片扫描仪是一种独特的扫描仪功能，引入了带有Perkin-Elmer的九色MIF 北极星系统创建的过程以识别和检索具有自定义临床变量的残余生物流体， 启动了视频通用电子同意，用于生物群，建立的研究血液吸血订单功能 常规临床实验室订单，合作处理UC虚拟生物库，并增加了生物流体的获取，处理和 贮存。 TPCL费用类似于或低于洛杉矶县其他癌症中心的费用。期间 前期项目期间，来自所有六项研究计划的153名JCCC成员均使用TPCL，占69％ 总体用法。它们的用法产生了334个出版物，其中49％处于高影响力（如果≥10，或字段 领导期刊。 TPCL位于大多数JCCC实验室的中心位置，占地约6,400平方英尺。 TPCL导演莎拉·德里（Sarah Dry），医学博士（ZY）和联合主任塞缪尔·法国（Samuel French），医学博士（ZY）和医学博士Dawn Ward是 经过董事会认证的实践病理学家，他们进行了基础，翻译和临床研究。自2013年以来，干燥 共同领导的UCLA生物库同意书，并在24个月内使用39,700份同意书，使用新颖的视频电子综合 过程。 Dry还发起了努力，导致当前与UC Davis在大学的TPCL合作 加利福尼亚（UC）虚拟生物库。 令人兴奋的未来TPCL方向支持和受益JCCC研究包括：（1）自动化是否/合并 如果/rna-ish染色； （2）增加对残留生物流体的临床变量搜索； （3）促进研究的使用 非临床医生的抽血要求； （4）UC虚拟生物库的持续发展。